Continuing Education Activity

This activity aligns with the American Board of Obesity Medicine's content blueprint for the Obesity Medicine board exam. Specifically, this course covers the material in the "A" duties of a physician (A: Evaluating, Examining, and Diagnosing) and the necessary task 12 in the outline (ie, A:12 in the exam blueprint): Diagnose genetic or syndromic causes of obesity. 

Genetic and syndromic causes of obesity represent a clinically significant subset of severe obesity that is often underrecognized in practice. These include monogenic disorders, such as leptin deficiency and melanocortin 4 receptor deficiency, as well as syndromic conditions like Prader-Willi syndrome and Bardet-Biedl syndrome. Patients frequently present with early-onset obesity, hyperphagia, dysmorphic features, or developmental delays that are easily overlooked during standard assessments. Delayed recognition leads to missed opportunities for early intervention and access to precision therapies. Advances in molecular diagnostics now allow more accurate characterization of these disorders. Still, many clinicians lack familiarity with the key red flags, testing strategies, and therapeutic pathways needed for timely diagnosis and management. Early recognition of genetic etiologies is essential for guiding appropriate care and improving long-term outcomes.

Participants in this activity learn systematic approaches for identifying genetic and syndromic obesity, including recognizing early clinical indicators, applying diagnostic algorithms, and using evidence-based genetic testing. Clinicians enhance competence in interpreting complex presentations, initiating referrals, and integrating therapeutic advances, including targeted therapies and coordinated behavioral strategies. Interactive case studies reinforce clinical reasoning and practical decision-making. The course also emphasizes interprofessional collaboration, illustrating how coordinated efforts among clinicians, geneticists, dietitians, endocrinologists, and mental health specialists enhance diagnostic accuracy and patient-centered care. 

Objectives:

• Implement standardized screening protocols incorporating validated questionnaires, growth monitoring, and developmental assessments across the lifespan.
• Interpret genetic testing results to diagnose patients with suspected monogenic or syndromic obesity.
• Evaluate patients to determine if they are appropriate candidates for targeted therapies based on their genetic diagnoses.
• Coordinate interprofessional team management involving endocrinology, genetics, nutrition, and behavioral health specialists to optimize comprehensive care for patients with genetic obesity syndromes.

Introduction

Genetic and epigenetic factors play a vital role in the pathogenesis of obesity. Obesity affects over 650 million adults worldwide, with most attributed to polygenic factors combined with environmental influences. While monogenic and syndromic forms of obesity are rare, recognizing them is essential, as accurate diagnosis directly informs targeted treatment strategies and optimizes patient outcomes. These genetic forms of obesity typically present with severe, early-onset obesity accompanied by distinctive clinical features that differentiate them from typical polygenic obesity.

The most studied monogenic form of obesity involves the leptin-melanocortin pathway, the central regulatory mechanism for energy homeostasis and appetite control. Monogenic obesity affects approximately 1% to 5% of individuals with severe, early-onset obesity, defined as obesity that begins before age 5 in children whose body mass index (BMI) is greater than the 95th percentile for age and sex. The most common monogenic causes involve disruptions in the leptin-melanocortin pathway, including leptin deficiency, leptin receptor (LEPR) deficiency, melanocortin-4 receptor (MC4R) deficiency, and proopiomelanocortin (POMC) or proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiencies.[1] Early recognition of genetic and syndromic causes of obesity is crucial for implementing appropriate interventions, providing genetic counseling, and optimizing long-term outcomes. The development of targeted therapies, eg, setmelanotide and diazoxide choline extended-release tablets, VYKAT XR, represents significant advances in the treatment of these previously difficult-to-manage conditions.

Epidemiology of Genetic Obesity

Twin studies have estimated the heritability of obesity to be between 40% and 70%. Over 100 genetic loci contribute to typical obesity, as identified through genome-wide association studies (GWAS). However, the identified loci explain only a small fraction of the heritability, a phenomenon known as the "missing heritability" problem. Possible explanations for this missing heritability include rare variants with large effect sizes, gene-gene interactions, and epigenetic modifications not captured in traditional GWAS studies.

Obesity Epigenetics

Epigenetic modifications, eg, deoxyribonucleic acid (DNA) methylation and histone modifications, influence gene expression without altering the underlying DNA sequence. Environmental factors, eg, maternal nutrition during pregnancy, can influence these modifications. For example, maternal undernutrition during pregnancy has been linked to an increased risk of obesity in offspring through epigenetic mechanisms that affect genes involved in metabolism and appetite regulation.

Red Flags for Genetic Obesity

Clinicians should request a referral for a genetic evaluation if any of the following red flag indicators are present in patients with obesity:

• Severe obesity onset before age 5 years
• Hyperphagia with food-seeking behaviors
• Obesity accompanied by developmental delays
• Obesity with distinctive dysmorphic features
• A family history of severe early-onset obesity
• Obesity and endocrine abnormalities (eg, hypogonadism and growth hormone deficiency)
• Obesity and vision problems or polydactyly
• A failure to respond to standard weight management interventions

Genetic Obesity Pathophysiology Overview

The pathophysiology of genetic obesity primarily involves disruption of the hypothalamic leptin-melanocortin pathway, which serves as the central regulatory system for energy homeostasis. This pathway begins with leptin, an adipocyte-derived hormone that signals satiety to the hypothalamus.[2] Please refer to the StatPearls companion resource, "Physiology, Leptin", for further information on leptin physiology. Within the hypothalamus, leptin signaling activates proopiomelanocortin (POMC) neurons, which produce α-melanocyte-stimulating hormone (α-MSH) through cleavage by proprotein convertase subtilisin/kexin type 1 (PCSK1). Melanocortin-4 receptors (MC4R) bind to α-MSH on downstream neurons, decreasing food intake and increasing energy expenditure.[3] Disruption at any point in this pathway results in severe obesity characterized by hyperphagia, reduced satiety, and decreased energy expenditure. The severity of the phenotype often correlates with the degree of pathway disruption, with complete deficiencies producing more severe obesity than partial deficiencies (see Table 1).[4]

Table

Table 1. Clinical Features of Genetic Obesity Syndromes.

Table

Table Pause and Reflect.

Function

Monogenic Obesity Disorders

Leptin and leptin receptor deficiency

Congenital leptin deficiency represents one of the most severe forms of monogenic obesity, typically manifesting in early infancy with rapid weight gain, severe hyperphagia, and frequent infections due to immune dysfunction (see Table 2).[5] Treatment with recombinant leptin (metreleptin) has demonstrated remarkable efficacy in patients with leptin deficiency, resulting in sustained weight loss and improved metabolic parameters.[6]

Table

Table 2. Leptin Deficiency Clinical Pearls.

Melanocortin-4 receptor deficiency

MC4R deficiency represents the most common form of monogenic obesity, accounting for 2% to 6% of severe early-onset obesity cases. The condition is inherited in an autosomal dominant pattern with variable penetrance; however, compound heterozygotes and homozygotes typically exhibit more severe phenotypes.[7] A distinctive feature is increased linear growth in childhood, leading to greater adult height than predicted by obesity alone.[8] The clinical presentation includes severe early-onset obesity, hyperphagia, hyperinsulinemia, and increased lean body mass. Recent advances include the investigation of setmelanotide, an MC4R agonist, for MC4R pathway defects, though its efficacy in classical MC4R deficiency remains under investigation.[3]

Table

Table Pause and Reflect.

Syndromic Obesity Conditions

Syndromic forms of obesity, such as Prader-Willi syndrome, Bardet-Biedl syndrome, and Alström syndrome, are characterized by distinctive constellations of clinical features and specific inheritance patterns. Accurate diagnosis requires a high index of suspicion, careful recognition of these phenotypic patterns, and confirmation through targeted genetic testing when indicated.

 Prader-Willi syndrome

Prader-Willi syndrome (PWS) is the most common syndromic cause of obesity, occurring in approximately 1 in 15,000 to 20,000 births. The condition results from the loss of expression of paternally inherited genes on chromosome 15q11-q13. PWS is characterized by neonatal hypotonia followed by hyperphagia, distinctive facial features, and behavioral abnormalities (see Table 3).[9]

Individuals with PWS exhibit diagnostic features that fall into major and minor clinical criteria (see Table 4). Recognition of these features enables early diagnosis and intervention, which are critical for optimizing outcomes. The diagnosis relies on a point-based clinical scoring system that incorporates both major and minor criteria. This structured approach ensures clinicians apply consistent diagnostic standards across age groups, allowing for early identification and appropriate genetic confirmation of the syndrome.

Diagnosis requires the following scoring based on patient age:

• Age <3 years: 5 points (4 major criteria)
• Age ≥3 years: 8 points (5 major criteria)

Please refer to the StatPearls companion resource, "Prader-Willi Syndrome", for further information on the management of this condition.

Table

Table 3. Prader-Willi Syndrome Age-Related Features.

Table

Table 4. Prader-Willi Syndrome Diagnostic Criteria  .

Bardet-Biedl syndrome

Bardet-Biedl syndrome (BBS) is a rare autosomal recessive ciliopathy with an estimated prevalence of 1 in 140,000 to 160,000 births. However, due to founder effects, higher rates occur in specific populations, such as the Faroe Islands. The term "founder effects" refers to a rare pathogenic variant in a gene that becomes disproportionately common in a specific population due to descent from a small group of ancestors who carried that variant.

BBS results from mutations in at least 26 genes (BBS1–BBS26), which encode proteins involved in cilia function.[10] The condition affects multiple organ systems and typically presents with early-onset obesity and other distinctive features.[11] Individuals with BBS present with polydactyly, cognitive impairment, retinal dystrophy, renal abnormalities, and hypogonadism. Highlights of clinical features of BBS include:

• Ophthalmologic

  • Rod-cone dystrophy, leading to night blindness during early childhood, followed by progressive tunnel vision and eventual blindness
  • Onset: Typically occurs between the ages of 8 and 10 years old
• Renal

  • Structural abnormalities (cystic kidneys, calyceal abnormalities)
  • Functional defects (concentrating ability, progressive chronic kidney disease)
  • The primary cause of morbidity and mortality
• Endocrine

  • Central obesity with hyperphagia
  • Hypogonadism (especially males)
  • Diabetes mellitus risk
• Developmental

  • Mild-moderate intellectual disability
  • Learning difficulties
  • Speech and language delays

Individuals with BBS exhibit diagnostic features that fall into major and minor clinical criteria. The 6 major criteria include rod-cone dystrophy leading to progressive vision loss, postaxial polydactyly, central obesity, genital abnormalities, renal dysfunction, and learning disabilities or cognitive impairment. The minor criteria include speech or developmental delay, ataxia, diabetes, dental anomalies, congenital heart disease, and hepatic fibrosis. Clinicians diagnose patients who exhibit 4 major criteria or a combination of 3 major criteria and 2 minor criteria.[12][13]  There is no known cure for BBS. For obesity and hyperphagia,setmelanotide, an MC4R agonist, is approved and has demonstrated efficacy in reducing hyperphagia and body weight, with associated improvements in quality of life in children and adults with BBS.[10][11]          

Alström syndrome

Alström syndrome is a rare, autosomal recessive multisystem disorder characterized by early-onset obesity, progressive retinal dystrophy with vision impairment, sensorineural hearing loss, insulin resistance, diabetes, and cardiomyopathy. The estimated prevalence of Alström syndrome is between 1 in 100,000 and 1 in 1,000,000 individuals, with fewer than 1000 cases identified worldwide. Patients require consultation with specialists in endocrinology, genetics, and ophthalmology.[14][15] 

Table

Table Pause and Reflect.

Issues of Concern

Other Complex Syndromes Requiring Referral

Various additional syndromes present with obesity, accompanied by additional complex signs and symptoms that warrant specialized evaluation and targeted management.[16] 

• Albright hereditary osteodystrophy: This condition is characterized by short stature, obesity, a round facial appearance, and brachydactyly. Patients may also exhibit subcutaneous ossifications and hormone resistance, particularly involving parathyroid hormone and thyroid-stimulating hormone, necessitating referral to an endocrinologist for further evaluation. 
• Wilson-Turner syndrome: Patients present with X-linked intellectual disability, obesity, distinctive facial features, and behavioral abnormalities. Optimal care requires consultation with genetics and neurology.
• Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation, ROHHAD syndrome: This syndrome is characterized by rapid-onset obesity between ages 2 and 7, involving hypothalamic dysfunction, hypoventilation, and autonomic dysregulation. Patients with this rare condition require an urgent referral to pediatric intensive care and pulmonology due to potentially life-threatening complications. A genetic etiology has not been discovered for this syndrome.[17] 

Clinical Significance

Clinical Screening and Diagnostic Approach

Clinicians do not routinely recommend universal genetic testing for patients with obesity. Genetic testing should be considered in patients with early-onset severe obesity (before age 5), syndromic features, eg, developmental delays or dysmorphic features, a strong family history of severe obesity, or failure to respond to standard weight management interventions.

Physical examination protocol

A systematic approach to the physical examination can identify features suggestive of genetic obesity syndromes (see Table 6). The examination should be comprehensive, focusing on identifying dysmorphic features, growth abnormalities, and signs of involvement in associated organ systems. Early recognition of these signs can significantly impact diagnosis and treatment planning.

 Table 6. The Systematic Physical Examination in Patients with Suspected Genetic Obesity

Table

Clinical Feature Abnormal Findings

AHO, albright hereditary osteodystrophy; BBS, Bardet-Biedl syndrome; MC4R, melanocortin 4 receptor; POMC, proopiomelanocortin; PWS, Prader-Willi syndrome

Genetic testing approach

A structured genetic testing strategy supports the accurate diagnosis of monogenic and syndromic obesity, guiding appropriate clinical management. The patient's specific clinical presentation guides initial testing. In cases of isolated severe obesity accompanied by hyperphagia, clinicians should measure serum leptin levels, followed by sequencing of the MC4R gene if leptin levels appear normal. For infants displaying neonatal hypotonia that progresses to obesity, PWS methylation analysis remains the preferred diagnostic approach. When obesity occurs with polydactyly, a BBS gene panel should be performed. Obesity with associated developmental delay warrants a chromosomal microarray to detect underlying genomic abnormalities.

Second-line strategies provide additional diagnostic clarity when initial testing fails to identify a causative mutation. Whole-exome sequencing may reveal rare variants in genes not captured by targeted panels. A strong family history of early-onset obesity suggests the need for focused gene panels based on inheritance patterns. Clinicians should pursue syndrome-specific genetic testing in the presence of distinct syndromic features.

Genetic counseling plays a vital role throughout the diagnostic process. All patients should receive pretest counseling to review the purpose and scope of testing, discuss inheritance patterns, and consider implications for family planning. Psychosocial support is equally essential, especially for families navigating the challenges of a genetic diagnosis.

Table

Table Pause and Reflect.

Treatment and Management of Genetic Obesity

Targeted therapies

Recent advances in understanding the genetics of obesity have led to the development of targeted therapies that address the underlying pathophysiology (see Table 7). These therapies represent a paradigm shift from traditional weight management approaches to precision medicine based on a specific genetic diagnosis.[18] The development of these targeted treatments has significantly improved outcomes for patients with previously untreatable genetic forms of obesity.[18]

Table

Table 7. Targeted Therapies for Genetic Obesity .

 BBS, Bardet-Biedl syndrome; FDA, (United States) Food and Drug Administration; GLP-1, glucagon-like peptide-1; PWS, Prader-Willi syndrome

Recommended Long-term Monitoring Protocols

Structured monitoring protocols tailored to general and disorder-specific needs are recommended for long-term management of genetic obesity syndromes (see Table 8). 

Table

Table 8.  Recommended Long-term Monitoring .

 BBS, Bardet-Biedl syndrome; MC4R, melanocortin 4 receptor; PWS, Prader-Willi syndrome

Table

Table Pause and Reflect.

Other Issues

Long-term Outcomes and Prognosis

The long-term prognosis for genetic obesity syndromes varies significantly based on the specific condition, severity of clinical features, and treatment options. Early diagnosis and appropriate management can substantially improve long-term outcomes and quality of life. Recent therapeutic advances have improved outcomes for patients with leptin deficiency and certain mutations in the MC4R pathway. The Food and Drug Administration approval in March 2025 of diazoxide choline extended-release tablets, VYKAT XR, for PWS-associated hyperphagia, represents a significant advance in the field.[19][20]

Management pearls

Effective management of genetic and syndromic obesity requires tailored strategies that extend beyond standard approaches used for common forms of obesity. Key factors that clinicians should bear in mind when managing genetic obesity include:

• Traditional caloric restriction often fails to produce meaningful results.
• Structured meal planning, environmental control, and supervised food access help individuals with severe hyperphagia to consume less food.
• Behavioral interventions must address the unique challenges associated with hyperphagia.
• Successful management involves implementing targeted behavioral techniques, educating family members, and modifying the home environment, eg, using locked food storage to limit unauthorized access. 
• Ongoing monitoring remains a cornerstone of care.
• Regular assessments of weight and growth track overall progress, while condition-specific screenings detect early complications.
• Monitoring includes evaluating treatment responses and conducting psychosocial assessments to support mental health and adaptive functioning.
• Transition planning ensures continuity of care as patients move from pediatric to adult healthcare systems. Coordination includes securing insurance coverage for long-term treatments and addressing the future living needs of individuals who require ongoing supervision or support. 
• Monogenic and syndromic obesity should be suspected in patients with severe early-onset obesity, especially when accompanied by hyperphagia, developmental delays, or distinctive physical features.
• The leptin-melanocortin pathway is central to appetite regulation, and its disruption leads to severe obesity accompanied by hyperphagia.
• Targeted therapies are now available for several genetic causes of obesity, emphasizing the importance of accurate genetic diagnosis.
• Not all children with obesity should be tested for genetic mutations—clinical suspicion based on early onset, syndromic features, family history, or failure to respond to standard interventions should guide testing.
• As understanding of genetic obesity expands, additional therapeutic targets and treatment options will likely emerge, further improving outcomes for patients with these challenging conditions.

Enhancing Healthcare Team Outcomes

Caring for individuals with genetic obesity syndromes requires a coordinated interprofessional team approach, as these conditions involve multiple organ systems and require ongoing, specialized interventions. Collaboration among healthcare disciplines supports comprehensive, patient-centered care, improving short-term and long-term outcomes. Primary care physicians and advanced practitioners are responsible for recognizing red flag indicators, initiating diagnostic testing, and making appropriate referrals to genetics, endocrinology, and neurology specialists.

Endocrinologists play a central role in managing all genetic obesity syndromes through hormone replacement therapy, metabolic regulation, and the administration of targeted therapies. Geneticists contribute by confirming diagnoses, offering genetic counseling, and assisting families with reproductive planning. Ophthalmologists manage visual complications through regular monitoring and providing low-vision services in conditions such as BBS and Alström syndrome. Cardiologists monitor cardiovascular health in patients with BBS and Alström syndrome, while nephrologists provide renal monitoring and management due to the high risk of kidney involvement. Pulmonologists conduct sleep evaluations and deliver ventilatory support in syndromes with respiratory complications, eg, PWS and ROHHAD syndrome.

Nutrition specialists and registered dietitians support patients and their families through tailored dietary interventions and feeding therapy, particularly crucial during the early stages of development. Behavioral health professionals address hyperphagia and associated behavioral challenges through structured interventions, particularly in individuals with PWS, BBS, and MC4R deficiency. Nurses and pharmacists play vital roles in caring for patients with genetic obesity syndromes. Nurses provide education on the condition and treatment plan, coordinate care among specialists, monitor growth and comorbidities, and support adherence to nutrition, activity, and medication regimens. Pharmacists optimize medication management by reviewing prescriptions for efficacy, potential interactions, and side effects, educating patients and their families on proper use, and monitoring outcomes. 

This coordinated interprofessional model ensures the team focuses on each patient's complex needs. Successful care implementation requires ongoing communication, shared decision-making with families, and the integration of genetic counseling. The healthcare team can collaborate to coordinate diagnostic evaluations, develop individualized treatment plans, and improve long-term outcomes for patients and their families.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Ayers KL, Glicksberg BS, Garfield AS, Longerich S, White JA, Yang P, Du L, Chittenden TW, Gulcher JR, Roy S, Fiedorek F, Gottesdiener K, Cohen S, North KE, Schadt EE, Li SD, Chen R, Van der Ploeg LHT. Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment. J Clin Endocrinol Metab. 2018 Jul 01;103(7):2601-2612. [PMC free article: PMC7263790] [PubMed: 29726959]

2.

Obradovic M, Sudar-Milovanovic E, Soskic S, Essack M, Arya S, Stewart AJ, Gojobori T, Isenovic ER. Leptin and Obesity: Role and Clinical Implication. Front Endocrinol (Lausanne). 2021;12:585887. [PMC free article: PMC8167040] [PubMed: 34084149]

3.

Metzger PJ, Zhang A, Carlson BA, Sun H, Cui Z, Li Y, Jahnke MT, Layton DR, Gupta MB, Liu N, Kostenis E, Gavrilova O, Chen M, Weinstein LS. A human obesity-associated MC4R mutation with defective Gq/11α signaling leads to hyperphagia in mice. J Clin Invest. 2024 Jan 04;134(4) [PMC free article: PMC10869179] [PubMed: 38175730]

4.

Izquierdo AG, Crujeiras AB, Casanueva FF, Carreira MC. Leptin, Obesity, and Leptin Resistance: Where Are We 25 Years Later? Nutrients. 2019 Nov 08;11(11) [PMC free article: PMC6893721] [PubMed: 31717265]

5.

ElSaeed G, Mousa N, El-Mougy F, Hafez M, Khodeera S, Alhelbawy M, Fouda E, Elsheikh S, ElKaffas R, Eldeeb S, Elsharkawy M. Monogenic leptin deficiency in early childhood obesity. Pediatr Obes. 2020 Jan;15(1):e12574. [PubMed: 31483094]

6.

Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, Digby JE, Mohammed SN, Hurst JA, Cheetham CH, Earley AR, Barnett AH, Prins JB, O'Rahilly S. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature. 1997 Jun 26;387(6636):903-8. [PubMed: 9202122]

7.

Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O'Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med. 2003 Mar 20;348(12):1085-95. [PubMed: 12646665]

8.

Martinelli CE, Keogh JM, Greenfield JR, Henning E, van der Klaauw AA, Blackwood A, O'Rahilly S, Roelfsema F, Camacho-Hübner C, Pijl H, Farooqi IS. Obesity due to melanocortin 4 receptor (MC4R) deficiency is associated with increased linear growth and final height, fasting hyperinsulinemia, and incompletely suppressed growth hormone secretion. J Clin Endocrinol Metab. 2011 Jan;96(1):E181-8. [PubMed: 21047921]

9.

Daley SF, Fermin Gutierrez MA, Mendez MD. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Dec 13, 2025. Prader-Willi Syndrome. [PubMed: 31985954]

10.

Dollfus H, Lilien MR, Maffei P, Verloes A, Muller J, Bacci GM, Cetiner M, van den Akker ELT, Grudzinska Pechhacker M, Testa F, Lacombe D, Stokman MF, Simonelli F, Gouronc A, Gavard A, van Haelst MM, Koenig J, Rossignol S, Bergmann C, Zacchia M, Leroy BP, Mosbah H, Van Eerde AM, Mekahli D, Servais A, Poitou C, Valverde D. Bardet-Biedl syndrome improved diagnosis criteria and management: Inter European Reference Networks consensus statement and recommendations. Eur J Hum Genet. 2024 Nov;32(11):1347-1360. [PMC free article: PMC11576898] [PubMed: 39085583]

11.

Shoemaker A. Bardet-Biedl syndrome: A clinical overview focusing on diagnosis, outcomes and best-practice management. Diabetes Obes Metab. 2024 Apr;26 Suppl 2:25-33. [PubMed: 38383825]

12.

Beales PL, Elcioglu N, Woolf AS, Parker D, Flinter FA. New criteria for improved diagnosis of Bardet-Biedl syndrome: results of a population survey. J Med Genet. 1999 Jun;36(6):437-46. [PMC free article: PMC1734378] [PubMed: 10874630]

13.

Melluso A, Secondulfo F, Capolongo G, Capasso G, Zacchia M. Bardet-Biedl Syndrome: Current Perspectives and Clinical Outlook. Ther Clin Risk Manag. 2023;19:115-132. [PMC free article: PMC9896974] [PubMed: 36741589]

14.

Sinha A, Leeson-Beevers K, Lewis C, Loughery E, Geberhiwot T. Alström syndrome: the journey to diagnosis. Orphanet J Rare Dis. 2025 Jan 06;20(1):5. [PMC free article: PMC11705659] [PubMed: 39763001]

15.

Han JC, Reyes-Capo DP, Liu CY, Reynolds JC, Turkbey E, Turkbey IB, Bryant J, Marshall JD, Naggert JK, Gahl WA, Yanovski JA, Gunay-Aygun M. Comprehensive Endocrine-Metabolic Evaluation of Patients With Alström Syndrome Compared With BMI-Matched Controls. J Clin Endocrinol Metab. 2018 Jul 01;103(7):2707-2719. [PMC free article: PMC6276679] [PubMed: 29718281]

16.

Khan SA, Muhammad N, Khan MA, Kamal A, Rehman ZU, Khan S. Genetics of human Bardet-Biedl syndrome, an updates. Clin Genet. 2016 Jul;90(1):3-15. [PubMed: 26762677]

17.

Filippidou M, Petropoulou T, Botsa E, Vasilakis IA, Smyrnaki P, Orfanou I, Kaditis A, Kanaka-Gantenbein C. ROHHAD syndrome - A still unrecognized cause of childhood obesity: report of three cases. J Pediatr Endocrinol Metab. 2020 Sep 30;33(10):1341-1348. [PubMed: 32990648]

18.

Clément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, De Waele K, Farooqi IS, Gonneau-Lejeune J, Gordon G, Kohlsdorf K, Poitou C, Puder L, Swain J, Stewart M, Yuan G, Wabitsch M, Kühnen P., Setmelanotide POMC and LEPR Phase 3 Trial Investigators. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020 Dec;8(12):960-970. [PubMed: 33137293]

19.

Miller JL, Gevers E, Bridges N, Yanovski JA, Salehi P, Obrynba KS, Felner EI, Bird LM, Shoemaker AH, Angulo M, Butler MG, Stevenson D, Abuzzahab J, Barrett T, Lah M, Littlejohn E, Mathew V, Cowen NM, Bhatnagar A., DESTINY PWS Investigators. Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial. J Clin Endocrinol Metab. 2023 Jun 16;108(7):1676-1685. [PMC free article: PMC10271219] [PubMed: 36639249]

20.

Miller JL, Gevers E, Bridges N, Yanovski JA, Salehi P, Obrynba KS, Felner EI, Bird LM, Shoemaker AH, Angulo M, Butler MG, Stevenson D, Goldstone AP, Wilding J, Lah M, Shaikh MG, Littlejohn E, Abuzzahab MJ, Fleischman A, Hirano P, Yen K, Cowen NM, Bhatnagar A., C601/C602 Investigators. Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label study. Obesity (Silver Spring). 2024 Feb;32(2):252-261. [PMC free article: PMC12181816] [PubMed: 37919617]

Disclosure: Venkata Sushma Chamarthi declares no relevant financial relationships with ineligible companies.

Disclosure: Sharon Daley declares no relevant financial relationships with ineligible companies.